Heart Failure with Reduced EF (HFrEF)
Four Pillars of GDMT — From Neurohormonal Activation to Mortality Reversal
Heart failure with reduced ejection fraction (HFrEF) is defined as a clinical syndrome of dyspnea, fatigue, and volume overload in the setting of an LVEF (left ventricular ejection fraction — the fraction of blood pumped out with each beat) at or below 40%.[1] It currently affects over 60 million people worldwide, and its five-year mortality rivals that of many solid-organ cancers. The condition is not one disease but a final common pathway of cardiac injury — from ischemia, toxins, infections, or genetics — that triggers a cascade of compensatory responses the body cannot sustain. The central management principle is straightforward to state and difficult to execute: four drug classes have independently proven mortality benefit, and combining all four is among the most powerful interventions in cardiovascular medicine. That combination — an ARNI (sacubitril-valsartan) or ACE inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor — constitutes guideline-directed medical therapy (GDMT). Patients on all four pillars can reduce their relative risk of death by approximately 75% compared to placebo. No other condition in cardiovascular medicine offers this magnitude of pharmacologic mortality reversal.
The story of heart failure treatment begins in 1785, with an old woman in Shropshire, England, who had a secret herbal remedy for dropsy — the swollen legs and bellies that physicians of the time could describe but could not cure. A local doctor named William Withering, out of professional curiosity, obtained her recipe. It contained no fewer than twenty herbs, but for a botanist and physician of Withering's caliber, the active ingredient was immediately apparent: foxglove, Digitalis purpurea. Over the following decade, Withering prescribed digitalis infusions to thousands of impoverished patients flooding his practice in Birmingham. He published his findings in An Account of the Foxglove in 1785, carefully documenting which patients improved — those with "dropsical" symptoms driven by cardiac decompensation — and which did not. He communicated his results to the Society of Medicine at Edinburgh, noting with characteristic precision that the drug was powerfully effective against dropsy caused by cardiac disease, but "I should not like to see it used in an unlimited manner as had hitherto been done." What Withering had discovered was not a cure, but the first agent in history capable of reducing the volume overload of a failing heart.
For nearly two centuries, digitalis and diuretics were the only tools available. The former strengthened the heartbeat; the latter drained the fluid. Neither changed the fundamental trajectory of the disease. Heart failure remained one of the most lethal diagnoses in medicine, with many patients dying within years of a new diagnosis. The watershed moment arrived in 1987, when the CONSENSUS trial randomized 253 patients with severe heart failure to enalapril — an ACE inhibitor, a drug that blocks a hormone system called the renin-angiotensin-aldosterone system (RAAS), which drives the heart to pump harder and retain sodium — or placebo.[2] The trial was stopped early. Mortality at six months was 44% in the placebo group versus 26% in the enalapril group — a 40% relative reduction. For the first time in history, a drug had reversed the natural history of heart failure.
The ACE inhibitor revolution was followed in the late 1990s by two more landmark discoveries. Carvedilol and metoprolol succinate — beta-blockers that had long been thought contraindicated in heart failure because they slow the heart — were shown in large trials to dramatically reduce mortality in HFrEF. The MERIT-HF trial with metoprolol succinate (1999) demonstrated a 34% relative risk reduction in all-cause mortality.[3] The COPERNICUS trial with carvedilol (2001) showed a 35% relative risk reduction in mortality even in severe HFrEF with EF below 25%.[4] The RALES trial (1999) added spironolactone, a mineralocorticoid receptor antagonist (MRA) that blocks aldosterone — a hormone driving harmful cardiac fibrosis and sodium retention — showing a 30% mortality reduction in severe HFrEF.[5] Three pillars were now established.
The modern era began in 2014, when PARADIGM-HF demonstrated that sacubitril-valsartan (a single pill combining an ARB with a neprilysin inhibitor, which amplifies the heart's own beneficial natriuretic hormones) was superior to enalapril in reducing cardiovascular death or heart failure hospitalization by 20%.[6] Then came the SGLT2 inhibitors — a drug class developed for type 2 diabetes — which stunned the cardiology world by demonstrating profound mortality benefits in HFrEF regardless of diabetes status. DAPA-HF (2019) with dapagliflozin[7] and EMPEROR-Reduced (2020) with empagliflozin[8] established the fourth pillar. The result is that HFrEF now has four independent, synergistic, proven therapies — each discovered in a different decade, each adding survival benefit on top of the last.
The left ventricle's job is simple: fill with blood, then eject it. In HFrEF, the ejection step fails. The ventricle cannot contract forcefully enough to maintain adequate forward output, and the result is a drop in stroke volume — the volume pumped with each beat.[1] The body responds immediately, deploying three compensatory systems. The sympathetic nervous system (SNS) increases heart rate and contractility. The renin-angiotensin-aldosterone system (RAAS) retains sodium and water to increase preload — the volume of blood returning to the heart. Antidiuretic hormone (ADH) adds further water retention. Together, these responses prop up cardiac output in the short term — and destroy the heart in the long term.
The problem is that every one of these compensatory responses is maladaptive over time. Catecholamines from sustained SNS activation are directly toxic to cardiomyocytes (heart muscle cells). Aldosterone drives fibrosis — the replacement of functional myocardium with stiff, non-contracting scar tissue. The volume overload created by RAAS and ADH activation stretches the ventricular walls, triggering a remodeling process in which the LV dilates, becomes more spherical, and loses its efficient elliptical geometry. A larger, more spherical ventricle must generate higher wall tension (by LaPlace's law) to produce the same pressure, which increases oxygen demand while simultaneously reducing subendocardial perfusion. The result is a vicious cycle: cardiac injury triggers neurohormonal activation, which triggers further cardiac injury, which triggers more neurohormonal activation.
At the molecular level, sustained adrenergic stimulation downregulates beta-1 receptors on cardiomyocytes and activates fetal gene programs — the cell reverts toward patterns of gene expression seen in embryonic development, producing less efficient contractile proteins. Calcineurin-NFAT signaling pathways promote pathological hypertrophy. Reactive oxygen species generated by this neurohormonal storm promote apoptosis of cardiomyocytes, which are not replaced. The interstitium fills progressively with collagen. This is precisely why the four pillars of GDMT work. ACE inhibitors and ARBs block angiotensin II, interrupting RAAS-driven remodeling. Beta-blockers interrupt SNS-driven cardiomyocyte toxicity and allow beta-1 receptor upregulation — which is why LVEF often improves by 10–15 percentage points in patients who tolerate them. MRAs block aldosterone, stopping fibrosis at the source. SGLT2 inhibitors reduce intracardiac filling pressures and may directly reduce myocardial oxidative stress. None of these drugs simply manages symptoms — all of them modify the underlying biology that kills the heart.
The simplest and most actionable framework for assessing an HFrEF patient at the bedside is the two-by-two hemodynamic grid, which categorizes patients by perfusion (warm vs. cold) and congestion (wet vs. dry).[1] Most outpatient HFrEF patients are warm and dry — compensated. Most hospital admissions are warm and wet. The dangerous quadrant is cold and wet.
Perfusion: Adequate (warm extremities, intact mentation, normal pulse pressure)
Congestion: Absent (no JVD, no rales, no edema)
Goal: Optimize and up-titrate GDMT. Target evidence-based doses.
Perfusion: Adequate (warm extremities)
Congestion: Present (elevated JVP, rales, edema, orthopnea)
Goal: Diuresis. Continue GDMT if tolerated. Most common admission profile.
Perfusion: Impaired (cool extremities, narrow pulse pressure, fatigue)
Congestion: Absent
Goal: Careful fluid challenge. Consider vasodilator reduction. Rule out tamponade, RV failure. Rare but treacherous.
Perfusion: Severely impaired (cold limbs, altered mentation, oliguria, SBP <90)
Congestion: Severe (elevated JVP, rales, edema)
Goal: Emergent management. Inotropes, vasopressors, mechanical circulatory support. ICU.
Do not be fooled by preserved blood pressure. A patient in early cardiogenic shock may have a systolic BP of 100 mm Hg but a pulse pressure of 20 mm Hg — meaning the heart is barely moving blood. The proportional pulse pressure [(systolic minus diastolic) divided by systolic] below 25% correlates with a cardiac index below 2.2 L/min/m², indicating dangerously low forward output. Clinical signs of low perfusion include cool and mottled extremities, a narrow pulse pressure, altered mentation, falling urine output, and elevated lactate. In this setting, diuretics alone will cause hemodynamic collapse. The patient needs inotropic support (dobutamine), urgent hemodynamic evaluation, and consideration of mechanical circulatory support — intra-aortic balloon pump or a percutaneous LV assist device — as a bridge to definitive therapy or cardiac transplantation.
Heart failure is primarily a clinical diagnosis. No single test is required, and no single test is sufficient. The history and physical examination together carry substantial diagnostic weight, though their sensitivity and specificity vary considerably by finding.[1] Two findings are particularly important: elevated JVP (jugular venous pressure — the height of the venous blood column visible in the neck, reflecting right atrial pressure) and the S3 gallop. Both are difficult to elicit reliably, but both are highly specific when present. The absence of rales is deceptive — in chronic HFrEF, collateral lymphatics in the thoracic cavity reabsorb much of the interstitial fluid, so rales are commonly absent even with significantly elevated pulmonary pressures.
| Finding | Sensitivity | Specificity | Clinical Pearl |
|---|---|---|---|
| Elevated JVP (>8 cm H₂O) | ~39% | ~93% | Most specific single exam finding for elevated left-sided filling pressures. Difficult to assess in obesity; POCUS fills the gap. |
| S3 Gallop | ~31% | ~95% | When heard, highly specific for elevated filling pressure. Listen at apex with bell in left lateral decubitus. Hard to hear — POCUS is more reliable. |
| Rales (pulmonary crackles) | ~13–35% | ~72% | Surprisingly insensitive in chronic HFrEF — collateral lymphatics absorb fluid. More reliable in acute decompensation. |
| Peripheral edema | ~50% | ~78% | Nonspecific — also in venous insufficiency, obesity, hypoalbuminemia. Bilateral pitting edema more suggestive of cardiac etiology. |
| Displaced PMI (>5 cm lateral to midclavicular line) | ~55% | ~85% | Suggests LV enlargement. Most specific on physical exam for dilated cardiomyopathy. Confirmed by echo. |
| Hepatojugular reflux | ~24% | ~96% | Apply sustained pressure to RUQ — JVP rise ≥3 cm suggests elevated right-sided filling pressures. Highly specific when positive. |
| Proportional pulse pressure <25% | ~62% | ~86% | [(SBP−DBP)/SBP] <25% suggests cardiac index <2.2 L/min/m². A simple bedside calculation — requires only a BP cuff. |
Point-of-care ultrasound (POCUS) transforms the physical examination of a heart failure patient from indirect inference to direct visualization. Where the stethoscope tells you a heart sound is abnormal, POCUS shows you the dilated left ventricle, the congested lungs, and the distended vena cava — simultaneously, at the bedside, in real time. As Larry Istrail, MD writes in The POCUS Textbook (2025): the clinician can "digitally peel back the epidermis and observe the ecosystem of internal organs functioning in real-time" — a capacity that should be impossible to leave unused at the bedside of any HFrEF patient.[9]
Pearl 1 — Visual EF Estimation (Parasternal Long Axis): In HFrEF, the LV is dilated and its walls barely squeeze inward with systole. A normal LV contracts like a fist closing — the endocardial borders of the posterior wall and interventricular septum nearly meet at peak systole. In HFrEF, this excursion is visually diminished. The E-point septal separation (EPSS) — the minimum distance between the anterior mitral valve leaflet and the interventricular septum on M-mode — is normally under 7 mm. Values above 10 mm strongly suggest reduced LVEF (sensitivity approximately 91%, specificity approximately 75%).[9] This single measurement takes 30 seconds and requires no Doppler.
Pearl 2 — B-lines for Pulmonary Congestion (Lung Ultrasound): B-lines are bright, laser-like vertical artifacts arising from the pleural line and extending to the bottom of the screen without fading — caused by thickened interlobular septa in pulmonary edema. Three or more B-lines per intercostal space, in multiple zones bilaterally, indicates pulmonary congestion. In ambulatory HFrEF patients, lung ultrasound B-lines independently predicted hospitalization and death at 6 months. Crucially, 81% of patients with pathological B-lines had no rales on auscultation — meaning lung ultrasound detects subclinical congestion long before the stethoscope does.[10]
Pearl 3 — IVC for Volume Status (Subcostal View): The inferior vena cava (IVC) — the large vein returning blood to the right atrium — can be measured in the subcostal view just caudal to the right atrium. A plethoric IVC (diameter greater than 2.1 cm with less than 50% inspiratory collapse) indicates elevated right atrial pressure of at least 10 mm Hg with sensitivity 89% and specificity 86%.[11] In advanced HFrEF with volume overload, the IVC is dilated and non-collapsible. After diuresis, its collapse index improves — making it a dynamic tool for monitoring therapeutic response.
Pearl 4 — LA Dilation as a Chronometer: On the parasternal long axis view, the left atrium (LA) is visible posterior to the aortic root. Normal LA diameter is at most 4.0 cm. LA dilation reflects chronically elevated left-sided filling pressures — it tells you how long the LV has been struggling. A markedly dilated LA (5 cm or more) in HFrEF signals sustained congestion, increased atrial fibrillation risk, and worse prognosis. Unlike symptoms, which fluctuate day to day, LA size reveals the cumulative burden over months.
Clinical Pearls for POCUS in HFrEF:
The diagnosis of HFrEF is confirmed by echocardiography, but the initial workup requires a broader laboratory evaluation to identify etiology, guide therapy, and establish baseline values before starting GDMT.[1]
Natriuretic Peptides (BNP and NT-proBNP) are the most useful biomarkers in heart failure. BNP is secreted by ventricular myocardium in response to wall stress. A normal BNP below 100 pg/mL in an untreated patient effectively rules out significant cardiac disease as the cause of dyspnea. NT-proBNP has a longer half-life and uses age-stratified cutoffs for acute dyspnea: below 450 for patients under 50, below 900 for ages 50–75, below 1800 for those over 75. One important caveat: sacubitril-valsartan inhibits neprilysin, the enzyme that degrades BNP, so BNP rises artifactually on this drug. Patients on sacubitril-valsartan should be followed with NT-proBNP, not BNP.
Basic Metabolic Panel: Creatinine and eGFR must be checked before starting RAAS-blocking agents, as ACE inhibitors, ARBs, and MRAs all affect renal perfusion and potassium handling. Potassium above 5.0 mEq/L is a contraindication to MRA initiation. Sodium below 130 mEq/L (hyponatremia) in HFrEF reflects severe neurohormonal activation driven by ADH and carries a markedly poor prognosis.
CBC: Anemia worsens HFrEF by increasing cardiac demand and reducing oxygen delivery. Iron deficiency is present in approximately 50% of HFrEF patients even without overt anemia. Intravenous iron repletion — not oral, which is poorly absorbed in HFrEF — improves symptoms and exercise tolerance in iron-deficient patients.
Thyroid Function (TSH): Both hypothyroidism and hyperthyroidism can cause or exacerbate cardiomyopathy. TSH should be measured in all new-onset HFrEF before attributing the diagnosis to other causes.
Echocardiogram Parameters: The transthoracic echocardiogram is the cornerstone of HFrEF evaluation. Key parameters include: LVEF (the defining metric; values at or below 40% establish HFrEF), LV end-diastolic dimension (LVEDD — normal below 5.5 cm; dilation above 6 cm confirms dilated cardiomyopathy), global longitudinal strain (GLS — a more sensitive measure of systolic function that can detect subclinical dysfunction before LVEF falls; normal values more negative than negative 18%), and left atrial volume index (LAVI — the best marker of cumulative diastolic burden; normal below 34 mL/m²; elevated values predict AF, stroke, and mortality).
Every patient with HFrEF and LVEF at or below 40% who can tolerate them should receive all four pillars of GDMT. The evidence supporting each comes from large, randomized, placebo-controlled trials with hard endpoints — mortality and hospitalization — not surrogate markers.[13]
| Intervention | When & How | Evidence & Key Points |
|---|---|---|
| ARNI (Sacubitril-valsartan) |
Preferred over ACEi in all eligible HFrEF patients. Start 24/26 mg BID, titrate to 97/103 mg BID. Requires 36-hour washout from ACEi to avoid angioedema. Hold if SBP <90. | PARADIGM-HF: 20% RRR in CV death or HF hospitalization vs. enalapril. NNT ~21 to prevent one primary endpoint at 27 months.[6] Superior to ACEi — not merely non-inferior. |
| ACE Inhibitor / ARB (if ARNI not tolerated) |
Lisinopril, enalapril (ACEi) or valsartan, losartan (ARB) if ACEi causes cough. Target evidence-based doses. Do not combine ACEi + ARB. | CONSENSUS: 40% RRR mortality with enalapril vs. placebo in NYHA IV HFrEF.[2] ACEi remain acceptable when ARNI is not tolerated or not affordable. |
| Beta-Blocker (carvedilol, metoprolol succinate, bisoprolol) |
Start only when euvolemic — never in acute decompensation. Begin low (carvedilol 3.125 mg BID, metoprolol XL 12.5–25 mg daily). Titrate slowly over weeks. Do NOT use metoprolol tartrate (short-acting). | MERIT-HF: 34% RRR mortality with metoprolol succinate.[3] COPERNICUS: 35% RRR mortality with carvedilol even in severe HFrEF (EF <25%).[4] |
| MRA (Spironolactone, Eplerenone) |
Add when EF ≤35% and NYHA II–IV symptoms. Start spironolactone 25 mg daily. Check K⁺ and creatinine at 1–2 weeks. Hold if K⁺ >5.0 or eGFR <30. Switch to eplerenone for gynecomastia. | RALES: 30% RRR mortality with spironolactone in severe HFrEF.[5] Eplerenone (EMPHASIS-HF) proven in NYHA II. Gynecomastia affects ~10% of men on spironolactone. |
| SGLT2 Inhibitor (Dapagliflozin, Empagliflozin) |
Add regardless of diabetes status. Dapagliflozin 10 mg or empagliflozin 10 mg daily. Generally safe to eGFR ≥20. Hold before procedures (risk of euglycemic diabetic ketoacidosis). Monitor for genital infections. | DAPA-HF: 26% RRR in composite of CV death, worsening HF, or hospitalization.[7] EMPEROR-Reduced: 25% RRR in CV death or HF hospitalization.[8] Benefits independent of diabetes status in both trials. |
| Loop Diuretics (Furosemide, Torsemide, Bumetanide) |
For symptom relief in volume-overloaded patients. Dose to achieve euvolemia. Torsemide has superior bioavailability to furosemide. Monitor electrolytes and creatinine. Add metolazone for diuretic resistance. | No randomized mortality data. Improve symptoms and exercise tolerance. Diuretic resistance: increase dose, switch agents, or add a thiazide diuretic for sequential nephron blockade at the distal tubule. |
| ICD (Implantable Cardioverter-Defibrillator) |
EF ≤35% after at least 3 months of optimized GDMT, NYHA II–III symptoms, life expectancy greater than 1 year with good functional status. Wait at least 40 days post-MI before implantation. | SCD-HeFT: 23% RRR in all-cause mortality with ICD vs. placebo in NYHA II–III with EF ≤35%.[14] MADIT-II: 31% RRR in mortality for ischemic cardiomyopathy with EF ≤30%.[15] |
| CRT (Cardiac Resynchronization Therapy) |
EF ≤35% plus LBBB plus QRS duration at or above 150 ms plus sinus rhythm. Add defibrillator function (CRT-D) in eligible patients. Can substantially reverse LV remodeling when criteria are met. | Class I recommendation per ACC/AHA/HFSA 2022 guideline.[13] Resynchronizes the dyssynchronous LV — the ventricle contracts as a coordinated unit rather than in opposing segments — improving EF, reducing hospitalization, and extending survival. |
| Key Recommendations — ACC/AHA/HFSA 2022 Heart Failure Guideline[13] | ||
|---|---|---|
| Class | Recommendation | Evidence Level |
| I | ARNI (sacubitril-valsartan) recommended in symptomatic HFrEF patients to reduce morbidity and mortality | Level A |
| I | Beta-blocker therapy (carvedilol, metoprolol succinate, bisoprolol) for all stable HFrEF patients | Level A |
| I | MRA (spironolactone or eplerenone) for HFrEF with NYHA II–IV symptoms and eGFR >30 mL/min | Level A |
| I | SGLT2 inhibitor (dapagliflozin or empagliflozin) to reduce HF hospitalization and CV mortality in HFrEF | Level A |
| I | ICD for primary prevention in HFrEF: EF ≤35%, NYHA II–III, optimal GDMT for ≥3 months, life expectancy >1 year | Level A |
| I | CRT for HFrEF: EF ≤35%, LBBB morphology, QRS ≥150 ms, in sinus rhythm on GDMT | Level A |
| IIa | Ivabradine for stable HFrEF in sinus rhythm with resting HR ≥70 bpm on maximally tolerated beta-blocker | Level B-R |
| IIa | Hydralazine-isosorbide dinitrate for self-identified Black patients with NYHA III–IV HFrEF on GDMT | Level A |
| IIb | Digoxin may be considered to reduce HF hospitalizations in patients remaining symptomatic on optimized GDMT | Level B-R |
For decades, the textbook approach to HFrEF was sequential: start an ACEi, wait weeks for the patient to tolerate it, add a beta-blocker, wait, add an MRA, then eventually consider an ARNI upgrade. In practice, this stepwise strategy meant many patients spent months — or years — without the full benefit of all four pillars. Patients who decompensated before reaching target doses were often never retried on the agents that were held. The evidence now strongly supports a different approach: simultaneous low-dose initiation of all four pillars, followed by parallel up-titration.
The STRONG-HF trial (2022) randomized 1,078 patients hospitalized for acute heart failure to either high-intensity GDMT initiation — rapid titration of all agents to 50% of target doses within 2 weeks of discharge and to target doses by 6 weeks — versus usual care. The high-intensity strategy reduced the primary composite of HF readmission or all-cause death at 180 days from 23% to 15% — a 34% relative risk reduction — with no increase in serious adverse events. The message was unambiguous: the risk of under-treating too slowly exceeds the risk of initiating too aggressively.
Practical approach for inpatient GDMT initiation: If the patient is euvolemic, start a beta-blocker (carvedilol 3.125 mg BID or metoprolol succinate 12.5 mg daily) at discharge. Start ARNI simultaneously at low dose (sacubitril-valsartan 24/26 mg BID) — there is no requirement to begin an ACEi first if no prior intolerance. Add spironolactone 25 mg if eGFR is above 30 and potassium is below 5.0. Add dapagliflozin 10 mg or empagliflozin 10 mg. These four drugs share no class interactions — all can be started on the same day. Schedule a follow-up at 1–2 weeks for BMP (creatinine, potassium) and vital signs, then titrate toward target doses aggressively.
One nuance worth knowing: SGLT2 inhibitors modestly lower potassium, which partially offsets MRA-induced hyperkalemia — making the combination of all four pillars easier to achieve in practice than when the regimen consisted of only three agents (ACEi plus beta-blocker plus MRA), which all raised potassium or lowered blood pressure in the same direction. The addition of the fourth pillar does not worsen the tolerability profile of the other three. If anything, it improves it.
Sacubitril-valsartan vs. enalapril in HFrEF. Definitive evidence that ARNI is superior to ACEi — a practice-changing result that replaced enalapril as the standard of care RAAS agent in HFrEF.
Dapagliflozin in HFrEF regardless of diabetes status. Established SGLT2 inhibitors as the fourth pillar of GDMT with a 26% relative risk reduction in the primary composite endpoint.
Enalapril in severe HFrEF. The first trial to demonstrate a drug could reduce mortality in heart failure — a 40% relative risk reduction that launched the neurohormonal era of HF treatment.
Comprehensive evidence-based recommendations for heart failure management. Essential reference for GDMT target doses, device indications, and staging of HFrEF across the clinical spectrum.
[1] Khan MS, Vaduganathan M, Butler J. Chapter 48: Diagnosis and Management of Chronic Heart Failure – Updated January 2023. In: Fuster V, et al., eds. Fuster and Hurst's The Heart, 15th ed. McGraw Hill, 2023.
[2] CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35. PMID: 2883575. [PubMed]
[3] MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7. PMID: 10376614. [PubMed]
[4] Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001;344(22):1651–8. PMID: 11386263. [PubMed]
[5] Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med. 1999;341(10):709–17. PMID: 10471456. [PubMed]
[6] McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993–1004. PMID: 25176015. [PubMed]
[7] McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995–2008. PMID: 31535829. [PubMed]
[8] Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413–1424. PMID: 32865377. [PubMed]
[9] Istrail L. The POCUS Textbook: Learn Point-of-Care Ultrasound of the Blood Vessels, Heart, & Lungs. ZeroGray Publishing, 2025. Chapters 14 (Estimating LV Ejection Fraction), 15 (Volume Overload and Venous Congestion), 7 (Pulmonary Edema).
[10] Platz E, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J. 2016;37(15):1244–1251. PMID: 26819225. [PubMed]
[11] Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol. 1990;66(4):493–496. PMID: 2386120. [PubMed]
[12] Scali MC, et al. Exercise-induced B-lines identify worse functional and prognostic stage in heart failure patients with depressed left ventricular ejection fraction. Eur J Heart Fail. 2017;19(11):1468–1478. PMID: 28198075. [PubMed]
[13] Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. J Am Coll Cardiol. 2022;79(17):1757–1780. PMID: 35379504. [PubMed]
[14] Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (SCD-HeFT). N Engl J Med. 2005;352(3):225–37. PMID: 15659722. [PubMed]
[15] Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (MADIT-II). N Engl J Med. 2002;346(12):877–83. PMID: 11907286. [PubMed]